The FDA approved the use of the vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist ramucirumab (Cyramza, Lilly) in combination with the epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) mutations.
“The approval of this new first-line … regimen, which inhibits the VEGFR and EGFR pathways together, is an important